WO2023094995 - HUMAN CXCL16 ANTIBODIES AND THE USE THEREOF
National phase entry:
Publication Number
WO/2023/094995
Publication Date
01.06.2023
International Application No.
PCT/IB2022/061294
International Filing Date
22.11.2022
Title **
[English]
HUMAN CXCL16 ANTIBODIES AND THE USE THEREOF
[French]
ANTICORPS HUMAINS CXCL16 ET LEUR UTILISATION
Applicants **
CELLUS, INC.
Inventors
CHO, Sun Wook
KIM, Seong Keun
Priority Data
10-2021-0164723
25.11.2021
KR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3340 | |
| EPO | Filing, Examination, Granting | 28097 | |
| Japan | Filing, Examination, Granting | 3083 | |
| South Korea | Filing, Examination, Granting | 2827 | |
| USA | Filing, Examination, Granting | 17340 |
Total:
54,687
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This application discloses a CXCL16 antibody for cancer treatment. In some embodiments, a CXCL16 antibody disclosed herein can inhibit the growth of cancer, for example, thyroid cancer, breast cancer, and prostate cancer. Also described is a combination of a CXCL16 antibody with a targeted anticancer agent and/or an immune checkpoint inhibitor for cancer treatment.[French]
La présente demande divulgue un anticorps CXCL16 pour le traitement du cancer. Dans certains modes de réalisation, un anticorps CXCL16 présentement divulgué peut inhiber la croissance du cancer, par exemple le cancer de la thyroïde, le cancer du sein et le cancer de la prostate. L'invention concerne également une combinaison d'un anticorps CXCL16 avec un agent anticancéreux ciblé et/ou un inhibiteur de point de contrôle immunitaire pour le traitement du cancer.